Results 71 to 80 of about 19,009 (196)
Background The DNA hypomethylating agents (HMAs) decitabine and azacitidine have been widely used in the management of elderly patients with acute myeloid leukemia (AML). However, no direct clinical trials have been carried out to compare the two agents.
Bingbing Wen +3 more
doaj +1 more source
Advances in the Role of Chemokines in Microwave Ablation‐Based Combinatorial Immunotherapy
MWA can initiate antitumor immunity through tumor antigen release and innate immune activation, but iMWA may instead promote an immunosuppressive microenvironment. Combining MWA with immunotherapeutic strategies offers a promising approach to enhance systemic immunity and suppress residual and distant tumors.
Ruijie An, Ningning He, Wendong Gu
wiley +1 more source
The effect of decitabine on megakaryocyte maturation and platelet release
SummaryThrombocytopenia is a common feature of myelodysplastic syndromes (MDS). 5-aza-2’-deoxycytidine (decitabine) has been used to treat MDS with an approximately 20% response rate in thrombocytopenia. However, the mechanism of how decitabine increases
Zanhua Yi +3 more
core +1 more source
A case of an early‐relapsed high‐risk T‐ALL with high BCL‐2 expression on leukemic blasts was successfully treated with decitabine and venetoclax, achieving a CR. We suggest decitabine and venetoclax should be synergistic in BCL2‐positive ALL.
Elisabetta Zappone +8 more
doaj +1 more source
PANoptosis in the pathogenesis of myelodysplastic syndromes
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla +4 more
wiley +1 more source
Abstract Background Elderly patients with acute myeloid leukemia (AML) treated with intensive chemotherapy are at risk of developing thrombopenia, which requires platelet transfusions. It would be interesting to provide them with thrombopoietin receptor agonists such as eltrombopag.
Arnaud Pigneux +24 more
wiley +1 more source
The type of DNA damage response after decitabine treatment depends on the level of DNMT activity
Chromatin-centred proteomics study in stem cells with different DNMT expression levels and activities reveals that decitabine invokes different DNA damage responses depending on the amount of the induced DNA-DNMT crosslinks.
Tina Aumer +9 more
doaj +1 more source
• DNMT3A‐mediated PDLIM4 promoter hypermethylation is an early event in colorectal tumorigenesis. • Restoring PDLIM4 suppresses CRC proliferation and stemness while promoting apoptosis in vitro and in vivo. • PDLIM4 promotes the autophagic‐lysosomal degradation of BTF3 and restrains PI3K/Akt signalling.
Jiaxing Wang +10 more
wiley +1 more source
Aberrant DNA methylation is one of the main drivers of tumor initiation and progression. The reversibility of methylation modulation makes it an attractive target for novel anticancer therapies.
Hui Fan +15 more
doaj +1 more source

